1. Academic Validation
  2. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway

Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway

  • Cell Oncol (Dordr). 2023 Apr 29. doi: 10.1007/s13402-023-00822-9.
Yiyi Ji # 1 Bo Liu # 1 Lei Chen # 1 Ang Li 1 Kai Shen 1 Ruopeng Su 1 Weiwei Zhang 1 Yinjie Zhu 2 Qi Wang 3 4 Wei Xue 5
Affiliations

Affiliations

  • 1 Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China.
  • 2 Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. yinjiezhu@outlook.com.
  • 3 Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. wqi@sjtu.edu.cn.
  • 4 Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China. wqi@sjtu.edu.cn.
  • 5 Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. uroxuewei@163.com.
  • # Contributed equally.
Abstract

Purpose: Neuroendocrine prostate Cancer (NEPC), a highly aggressive subtype of prostate Cancer displaying resistance to hormone therapy, presents a poor prognosis and limited therapeutic options. Here, we aimed to find novel medication therapies for NEPC and explore the underlying mechanism.

Methods: A high-throughput drug screening utilizing an FDA-approved drug library was performed and ketotifen, an antihistamine agent, was identified as a potential therapeutic candidate for NEPC. The whole-transcriptome Sequencing analysis was conducted to explore mechanism of ketotifen inhibitory in NEPC. Multiple Cell Biology and biochemistry experiments were performed to confirm the inhibitory effect of ketotifen in vitro. A spontaneous NEPC mice model (PBCre4:Ptenf/f;Trp53f/f;Rb1f/f) was used to reveal the inhibitory effect of ketotifen in vivo.

Results: Our in vitro experiments demonstrated that ketotifen effectively suppressed neuroendocrine differentiation, reduced cell viability, and reversed the lineage switch via targeting the IL-6/STAT3 pathway. Our in vivo results showed that ketotifen significantly prolonged overall survival and reduced the risk of distant metastases in NEPC mice model.

Conclusion: Our findings repurpose ketotifen for antitumor applications and endorse its clinical development for NEPC therapy, offering a novel and promising therapeutic strategy for this formidable Cancer subtype.

Keywords

Drug repurposing; High-throughput drug screening; IL-6/STAT3 pathway; Ketotifen; Lineage switch; NEPC.

Figures
Products